AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for selpercatinib RET fusion positive NSCLC
March 27, 2023 01:00 ET
|
PREMIA Holdings (HK) Ltd.
TOKYO and XIAMEN, China, March 27, 2023 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the...
Precision Medicine Asia and National Cancer Center Hospital East Announce the Initiation of the LC-SCRUM-AP Genomic Screening Platform for the Asia-Pacific Region
December 21, 2022 00:00 ET
|
PREMIA Holdings (HK) Ltd.
TOKYO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Precision Medicine Asia Co., Ltd. (“PREMIA”) and National Cancer Center Hospital East (“NCCHE”) announced the initiation of the Lung Cancer Genomic Screening...
AmoyDx and PREMIA Announce the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan
January 13, 2022 08:00 ET
|
PREMIA Holdings (HK) Ltd.
XIAMEN, China and HONG KONG, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Amoy Diagnostics Co., Ltd., (“AmoyDx”) and PREMIA Holdings (HK) Limited (“PREMIA”) today announced the commercial launch of the AmoyDx®...
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for TEPMETKO® (tepotinib)
August 16, 2021 22:00 ET
|
PREMIA Holdings (HK) Ltd.
TOKYO and XIAMEN, China, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the...
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer
June 30, 2021 00:01 ET
|
PREMIA Holdings (HK) Ltd.
TOKYO and XIAMEN, China, June 30, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the...
UPDATE – PREMIA and AmoyDx Announce Strategic Partnership to Establish Asia Cancer Clinical Genomic Network
June 24, 2019 20:18 ET
|
PREMIA Holdings (HK) Ltd.
HONG KONG, June 24, 2019 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, has entered into a strategic partnership agreement with Amoy Diagnostics Co.,...
PREMIA and AmoyDx Announce Strategic Partnership to Establish Asia Cancer Clinical Genomic Network
June 24, 2019 09:00 ET
|
PREMIA Holdings (HK) Ltd.
HONG KONG, June 24, 2019 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, has entered into a strategic partnership agreement with Amoy Diagnostics Co.,...